Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL10069639 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL8765516 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13813558 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1561081 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13800804 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1994014 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL2737 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22058352 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22163723 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL3121359 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-2010539-B1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | NEKTAR THERAPEUTICS (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20150166553-A1 | SYNTHESIS OF OXYCODONE HYDROCHLORIDE | CODY LABORATORIES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8183376-B2 | Stereoselective reduction of a morphinone | NEKTAR THERAPEUTICS (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090221766-A1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| US-7501433-B2 | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2009-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166553-A1 | SYNTHESIS OF OXYCODONE HYDROCHLORIDE | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20090221766-A1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | SORD, ADH1C, ADH1A | OPRM1 174/4885OPRD1 390/4885OPRK1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.